Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $357000.0.

  • Harvard Bioscience's Amortization of Deferred Charges rose 30112.36% to $357000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $796000.0, marking a year-over-year increase of 16622.07%. This contributed to the annual value of $327000.0 for FY2024, which is 1678.57% up from last year.
  • As of Q3 2025, Harvard Bioscience's Amortization of Deferred Charges stood at $357000.0, which was up 30112.36% from $210000.0 recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Amortization of Deferred Charges registered a high of $357000.0 during Q3 2025, and its lowest value of $70000.0 during Q1 2021.
  • Moreover, its 5-year median value for Amortization of Deferred Charges was $70000.0 (2021), whereas its average is $98157.9.
  • In the last 5 years, Harvard Bioscience's Amortization of Deferred Charges crashed by 2929.29% in 2021 and then soared by 30112.36% in 2025.
  • Harvard Bioscience's Amortization of Deferred Charges (Quarter) stood at $70000.0 in 2021, then changed by 0.0% to $70000.0 in 2022, then changed by 0.0% to $70000.0 in 2023, then soared by 40.0% to $98000.0 in 2024, then skyrocketed by 264.29% to $357000.0 in 2025.
  • Its Amortization of Deferred Charges stands at $357000.0 for Q3 2025, versus $210000.0 for Q2 2025 and $131000.0 for Q1 2025.